Suitability of infrared spectroscopy for drug checking in harm reduction centres.
暂无分享,去创建一个
R Goncalves | K Titier | V Latour | A Peyré | N Castaing | A Daveluy | M Molimard | M. Molimard | N. Castaing | K. Titier | A. Daveluy | A. Peyré | R. Goncalves | V. Latour
[1] M. Barratt,et al. The utility of drug checking services as monitoring tools and more: A response to Pirona et al. , 2017, The International journal on drug policy.
[2] R. Day,et al. Drug checking to improve monitoring of new psychoactive substances in Australia , 2016, The Medical journal of Australia.
[3] K. Pueschel,et al. Mass poisoning with NPS: 2C-E and Bromo-DragonFly , 2018, International Journal of Legal Medicine.
[4] R. de la Torre,et al. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study , 2018, Front. Pharmacol..
[5] M. Ray,et al. Fatal Toxic Leukoencephalopathy Secondary to Overdose of a New Psychoactive Designer Drug 2C-E (“Europa”) , 2012, Proceedings.
[6] E. Wood,et al. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. , 2018, Drug and alcohol dependence.
[7] M. Barratt,et al. Results of an international drug testing service for cryptomarket users. , 2016, The International journal on drug policy.
[8] M. Farré,et al. Patterns of use and toxicity of new para‐halogenated substituted cathinones: 4‐CMC (clephedrone), 4‐CEC (4‐chloroethcatinone) and 4‐BMC (brephedrone) , 2017, Human psychopharmacology.
[9] Kara L Lynch,et al. Role of liquid chromatography–high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology , 2012, Clinical toxicology.
[10] M. Farré,et al. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis , 2017, Journal of psychoactive drugs.
[11] M. Farré,et al. The hidden web and the fentanyl problem: Detection of ocfentanil as an adulterant in heroin. , 2017, The International journal on drug policy.
[12] Marcio Talhavini,et al. Discrimination and quantification of cocaine and adulterants in seized drug samples by infrared spectroscopy and PLSR. , 2015, Forensic science international.
[13] Jeff Powell,et al. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services , 2017, Harm Reduction Journal.
[14] S. Sherman,et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. , 2020, The International journal on drug policy.
[15] Susan G. Sherman,et al. Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study. , 2019, Drug and alcohol dependence.
[16] I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances. , 2017, The International journal on drug policy.
[17] Claudio Vidal Giné,et al. Crystals and tablets in the Spanish ecstasy market 2000-2014: Are they the same or different in terms of purity and adulteration? , 2016 .
[18] M. Barratt,et al. Pill testing or drug checking in Australia: Acceptability of service design features , 2018, Drug and alcohol review.
[19] E. Wood,et al. Detecting fentanyl using point-of-care drug checking technologies: A validation study. , 2020, Drug and alcohol dependence.
[20] T. Kerr,et al. "We don't got that kind of time, man. We're trying to get high!": Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs. , 2019, The International journal on drug policy.